YOLFTbeta
41

Orient Pharma Co. Ltd.

4166 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

21.60TWD-0.90 (-4.00%)

Price History

Full chart

Market Stats

Previous Close22.50
Open22.25
Day Range21.20 – 22.75
52-Week Range22.40 – 29.60
Volume518.29K
Market Cap5.93B
P/E (TTM)24.65
Forward P/E6.18
EPS0.99
Dividend Yield0.00%
Beta0.04
50-Day Avg24.46
200-Day Avg25.45

About

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Chun-Tong Huang
  • Employees0
  • HeadquartersCentral Science Park, Taipei, Taiwan, 106, Taiwan
  • Websitehttps://www.oppharma.com

Leadership

  • Mr. Chun-Tong HuangGeneral Manager
  • Yi Xin ZhangChief Financial Officer
  • Zhi Cheng LuChief Operating Officer
  • Mei Xiu HanAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue353.54M412.01M463.34M511.86M889.91M1.22B1.40B
Growth (%)-+16.54%+12.46%+10.47%+73.86%+37.41%+14.52%
Cost of Revenue339.85M336.86M320.67M356.51M421.25M571.26M609.66M
Gross Profit13.69M75.15M142.67M155.35M468.67M651.56M790.72M
Gross Margin3.87%18.24%30.79%30.35%52.66%53.28%56.46%
Operating Expense219.06M235.42M247.06M189.08M428.41M477.65M523.66M
Operating Income-205.37M-160.27M-104.39M-33.73M40.26M173.91M267.06M
Operating Margin-58.09%-38.90%-22.53%-6.59%4.52%14.22%19.07%
EBITDA-150.67M-93.70M-39.21M35.37M175.83M312.81M388.16M
EBITDA Margin-42.62%-22.74%-8.46%6.91%19.76%25.58%27.72%
Net Income-201.03M-171.38M-102.65M-28.76M22.29M107.37M208.44M
Net Income Margin-56.86%-41.59%-22.15%-5.62%2.50%8.78%14.88%
R&D153.62M183.94M219.72M129.25M99.90M103.72M79.93M
R&D as % of Total Revenue43.45%44.64%47.42%25.25%11.23%8.48%5.71%
Interest Expense4.93M5.38M5.70M7.37M13.90M13.97M7.91M
Interest Expense % of Total Revenue1.39%1.31%1.23%1.44%1.56%1.14%0.56%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.56B1.74B1.76B1.85B2.56B2.52B2.94B
Total Liabilities1.60M526.41M647.90M757.65M892.18M733.00M374.88M
Total Equity985.24M1.22B1.12B1.09B1.67B1.79B2.56B
Cash37.31M49.58M130.92M76.43M83.32M84.50M587.60M
Total Debt358.99M324.03M415.33M508.21M716.93M--
Net Debt321.69M274.45M284.41M431.78M633.61M247.90M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-129.91M-147.95M-53.56M11.38M-102.99M195.71M359.86M
Financing Cash Flow94.56M354.85M79.11M-36.79M197.90M--
Capital Expenditure25.40M74.43M70.00M28.92M73.51M27.42M49.49M
Free Cash Flow-155.30M-222.38M-123.56M-17.54M-176.51M168.29M310.36M
FCF to OCF119.55%150.31%230.68%-154.04%171.38%85.99%86.25%

Key Statistics & Ratios

Market Cap5.93B
Enterprise Value5.49B
Trailing P/E24.65
Forward P/E6.18
Price / Sales3.91
Price / Book2.21
EPS0.99
Book Value10.94
Revenue (TTM)1.52B
Gross Profit (TTM)852.35M
EBITDA394.58M
Profit Margin15.52%
Operating Margin18.26%
Return on Equity10.42%
Return on Assets6.29%
Shares Outstanding243.04M
Shares Float57.17M
Beta0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%